Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Animal or plant cell
Reexamination Certificate
2008-04-01
2008-04-01
Chan, Christina (Department: 1644)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Animal or plant cell
C435S325000
Reexamination Certificate
active
07351409
ABSTRACT:
The present invention relates to isolation of cytotoxic T lymphocyte (CTL) clones. In particular, the present invention relates to isolated CTL clones that are specific for proteins of the MAGE family. The CTL clones of the present invention have been isolated by successive steps of stimulation and testing of lymphocytes with antigen presenting cells which present antigens derived from different expression systems, e.g., from recombinantYersinia, recombinantSalmonella, or recombinant viruses. The present invention further relates to antigenic peptides as well as the peptide/HLA complexes which are recognized by the isolated CTL clones.
REFERENCES:
patent: 4769330 (1988-09-01), Paoletti et al.
patent: 5342774 (1994-08-01), Boon et al.
patent: 5558995 (1996-09-01), van der Bruggen et al.
patent: WO 94/03205 (1994-02-01), None
patent: WO 95/04542 (1995-02-01), None
patent: WO 95/21630 (1995-08-01), None
patent: WO 98/10780 (1998-03-01), None
patent: WO 99/14326 (1999-03-01), None
patent: WO 99/45954 (1999-09-01), None
The Free Dictionary. www.thefreedictionary.com/pharmaceutical, Jan. 26, 2007, one page.
Gao et al (J. Immunother. 23: 643-653, 2000).
Marchand et al (Exp. Opin. Biol. Ther. 1(3): 497-510, 2001).
Mitchell et al (J. Clin Oncol. 2002, 20(4): 1075-1086).
Farina et al (Int. Immunol. 1996, 8(9): 1463-1466).
Boel et al (Immunity, 1995, 2: 167-175).
Cox et al. (1993) “Induction of Cytotoxic T Lymphocytes by Recombinant Canarypox (ALVAC) and Attenuated Vaccinia (NYVAC) Viruses Expressing the HIV-1 Envelope Glycoprotein”,Virology, 195: 845-850.
Kim et al. (1997) “Dendritic Cells Infected with Poxviruses Encoding MART-1/Melan A Sensititve T Lymphocytes In Vitro”,Journal of Immunotherapy, 20(4): 276-286.
Knuth et al. (1989) “Cytolytic T-cell clones against an autologous human melanoma: Specificity study and definition of three antigens by immunoselection”,Proc. Natl. Acad. Sci. USA, 86: 2804-2808.
Russmann et al. (1998) “Delivery of Epitopes by the Salmonella Type III Secretion System for Vaccine Development”,Science, 281: 565-568.
Eitenne De Plaen, et al. (1994) “Structure, chromosomal localization, and expression of 12 genes of the MAGE family”,Immunogentics, 40: 360-369.
Darryl S. Reed, et al. (1997) “Construction and characterization of a recombinant adenovirus directing expression of the MAGE-1 tumor-specific antigen”,Int. J. Cancer, 72: 1045-1044.
Sory et al. (1994) “Translocation of a hybrid YopE-adenylate cyclase fromYersinia enterocoliticainto HeLa cells”,Molecular Microbiology, 14(3): 583-594.
Van Den Eynde et al. (1989) “Presence On A Human Melanoma Of Multiple Antigens Recognized By Autologous CTL”,Int. J. Cancer, 44: 634-640.
Chaux, et al. (1999) “Identification of Five MAGE-A1 Epitopes Recognized by Cytolytic T Lymphocytes Obtained by In Vitro Stimulation with Dendritic Cells Transduced withMAGE-A11”, J. Immunol, 163(5): 2928-2936.
Boon-Falleur Thierry
Chaux Pascal
Cornelis Guy R.
Demotte Nathalie
Duffour Marie-Therese
Chan Christina
DiBrino Marianne
Ludwig Institute for Cancer Research
Scully , Scott, Murphy & Presser, P.C.
LandOfFree
Tumor antigens and CTL clones isolated by a novel procedure does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor antigens and CTL clones isolated by a novel procedure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor antigens and CTL clones isolated by a novel procedure will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2748943